Abstract:Hyperglycemia is a risk factor for the development of insulin resistance, beta-cell glucotoxicity, and vascular complications of diabetes. We propose the hypothesis, hexokinase-linked glycolytic overload and unscheduled glycolysis, in explanation. Hexokinases (HKs) catalyze the first step of glucose metabolism. Increased flux of glucose metabolism through glycolysis gated by HKs, when occurring without concomitant increased activity of glycolytic enzymes—unscheduled glycolysis—produces increased levels of glycolytic intermediates with overspill into effector pathways of cell dysfunction and pathogenesis. HK1 is saturated with glucose in euglycemia and, where it is the major HK, provides for basal glycolytic flux without glycolytic overload. HK2 has similar saturation characteristics, except that, in persistent hyperglycemia, it is stabilized to proteolysis by high intracellular glucose concentration, increasing HK activity and initiating glycolytic overload and unscheduled glycolysis. This drives the development of vascular complications of diabetes. Similar HK2-linked unscheduled glycolysis in skeletal muscle and adipose tissue in impaired fasting glucose drives the development of peripheral insulin resistance. Glucokinase (GCK or HK4)-linked glycolytic overload and unscheduled glycolysis occurs in persistent hyperglycemia in hepatocytes and beta-cells, contributing to hepatic insulin resistance and beta-cell glucotoxicity, leading to the development of type 2 diabetes. Downstream effector pathways of HK-linked unscheduled glycolysis are mitochondrial dysfunction and increased reactive oxygen species (ROS) formation; activation of hexosamine, protein kinase c, and dicarbonyl stress pathways; and increased Mlx/Mondo A signaling. Mitochondrial dysfunction and increased ROS was proposed as the initiator of metabolic dysfunction in hyperglycemia, but it is rather one of the multiple downstream effector pathways. Correction of HK2 dysregulation is proposed as a novel therapeutic target. Pharmacotherapy addressing it corrected insulin resistance in overweight and obese subjects in clinical trial. Overall, the damaging effects of hyperglycemia are a consequence of HK-gated increased flux of glucose metabolism without increased glycolytic enzyme activities to accommodate it.

Direct Regulation of Glucose and Not Insulin on Hepatic Hexose-6-phosphate Dehydrogenase and 11Β-Hydroxysteroid Dehydrogenase Type 1

Interplay Between H6PDH and 11Β-Hsd1 Implicated in the Pathogenesis of Type 2 Diabetes Mellitus.

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

Specific Reduction of G6PT May Contribute to Downregulation of Hepatic 11Β-Hsd1 in Diabetic Mice.

11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes

Regulation of Hepatic Glucose Production by Transforming Growth Factor Beta 1 Via Protein Kinase A

Regulation of hepatic pyruvate dehydrogenase phosphorylation in offspring glucose intolerance induced by intrauterine hyperglycemia.

The expression of 11β-hydroxysteroid dehydrogenase in diabetes mellitus vasculopathy treated with different concentration of glucose

Unraveling the Regulation of Hepatic Gluconeogenesis

Enhanced Hexose-6-Phosphate Dehydrogenase Expression in Adipose Tissue May Contribute to Diet-Induced Visceral Adiposity

G 12/13 -mediated signaling stimulates hepatic glucose production and has a major impact on whole body glucose homeostasis

Role of serum- and glucocorticoid-inducible kinase 1 in the regulation of hepatic gluconeogenesis.

Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis of insulin resistance, beta-cell glucotoxicity, and diabetic vascular complications

Effects of Nutrients and Insulin on Transcriptional and Post-Transcriptional Regulation of Glucose-6-phosphate Dehydrogenase Synthesis in Rat Liver.

Glycolysis in the Control of Blood Glucose Homeostasis

The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy

Alteration of 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes

Hepatic IDH2 Regulates Glycolysis and Gluconeogenesis

Hexosamines and Insulin Resistance

Alteration of 11Β-Hydroxysteroid Dehydrogenase Type 1 and Glucocorticoid Receptor by Ethanol in Rat Liver and Mouse Hepatoma Cells

1303-P: Decreased Hepatic HMGB1 in Type 2 Diabetes Increases Mitochondrial Glucose Uptake by Regulating Insulin/AKT Signaling